Compare HAE & QTWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAE | QTWO |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 1996 | 2014 |
| Metric | HAE | QTWO |
|---|---|---|
| Price | $102.92 | $62.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $84.13 | $82.64 |
| AVG Volume (30 Days) | ★ 663.1K | 576.3K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | 0.72 | ★ 0.87 |
| Revenue | ★ $910,373,000.00 | $193,978,000.00 |
| Revenue This Year | N/A | $12.48 |
| Revenue Next Year | $5.23 | $10.18 |
| P/E Ratio | $142.94 | ★ $71.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.32 | $40.79 |
| 52 Week High | $109.57 | $85.19 |
| Indicator | HAE | QTWO |
|---|---|---|
| Relative Strength Index (RSI) | 62.29 | 58.94 |
| Support Level | $79.52 | $63.44 |
| Resistance Level | $109.57 | $66.50 |
| Average True Range (ATR) | 2.59 | 2.21 |
| MACD | -0.93 | -0.47 |
| Stochastic Oscillator | 62.50 | 50.91 |
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
Q2 Holdings Inc provides digital solutions to financial institutions, financial technology companies, and alternative finance companies, seeking to incorporate banking into their customer engagement and servicing strategies. The company helps its clients with supervisory, consumer protection, privacy, third-party risk management requirements, and cyber threats and fraud, among other applications, by offering a portfolio of digital solutions, which comprises its digital banking offerings, digital lending and relationship pricing solutions, risk and fraud solutions, as well as Q2 Innovation Studio and Helix. Q2 derives the majority of its revenue from subscription fees for the use of its hosted solutions.